TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06795061

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer-Supported Exercise with Professional Guidance
Description: Participants will engage in small, peer-supported exercise groups (4-6 individuals) to coordinate weekly sessions (e.g., running, cycling, yoga). A professional coach provides knowledge-based guidance remotely, focusing on safe exercise techniques, injury prevention, basic nutrition, and motivation strategies, but does not conduct in-person training sessions. The aim is to improve adherence to physical activity and enhance mental well-being through peer accountability and evidence-informed coaching.
Study: NCT06797193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Liver Biopsy
Description: Undergo liver biopsy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Undergo ultrasound with SHAPE technique

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Perflutren Lipid Microspheres
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: Undergo ultrasound
Study: NCT06797661

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional MRI
Description: 11 minutes of Functional MRI alternating breathing Air-Room and gaz mix (5%CO2 21%O2 74%N2).~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FDG-PET
Description: Some patients who did not benefit from a FDG-PET in their clinical evaluation or more than 1 month before the inclusion in the present study will be ask to also undergo a brain FDG-PET , the dose is set at 2 Mega becquerel per Kg.~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Structural MRI
Description: Patient will benefit Different anatomical sequence of acquisition listed here : T1 , T1 with contrast agent (gadovist) , T2 flair , T2 and DSC (Dynamic susceptibility contrast) , and Time Of Flight .~All procedure are acquired simultaneously on a single acquisition on the PET/MRI camera in the institution.
Study: NCT06797011

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High volume Plasma Exchange
Description: High volume Plasma Exchange with minimum 3 sessions on alternate days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
Study: NCT05343689

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pneumatic compression
Description: Pneumatic compression with preset pressure and cyclic manner is applied from immediately after anesthesia induction to 20 minutes after anesthesia induction in the both legs.
Study: NCT05513365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin 10.8 mg
Description: Goserelin injection (10.8 mg) once per 3 months until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicalutamide 50 mg
Description: Bicalutamide tablets (50 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study: NCT05434871

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga training
Description: There will be a 45-minute yoga session 2 days a week for 8 weeks. Warm up with yoga-specific moves for 10 minutes (light stretching), yoga postures for 25 minutes and rest and meditate for the last ten minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: The standard physiotherapy and rehabilitation program consists of strength, flexibility, balance, gait and coordination exercises 2 days a week for 8 weeks.
Study: NCT05463718

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: children treated by Virtual Reality for 15 min. besides the traditional physical therapy program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: children treated by Virtual Reality for 15 min. besides the traditional physical therapy program

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: children treated by Virtual Reality for 15 min. besides the traditional physical therapy program
Study: NCT06797011

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment includes stopping the offending drug,nutrition,injection NAC,Tablet UDCA,steroid in DILI AIH
Study: NCT06794411

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention group: Food habits and physical activity program
Description: 5 dynamic face-to-face sessions to promote healthy eating and regular physical activity. The 5 sessions are structured based on the pedagogical approach of Seeing, Judging and Acting (Gibson, 1999; Rodríguez-Bailón, et al., 2016). This methodology provides a logical structure to achieve nutritional and physical activity self-analysis. It is applied based on 3 stages:~* 1st reflective stage: to raise awareness about the importance of following healthy eating and physical activity habits and identify to what extent families are close to the healthy recommendations in relation to these two habits (first two sessions).~* 2nd: more active stage, to acquire strategies and learn to put these recommendations into practice in their day-to-day lives (session 3th and 4th session).~* 3th: to plan specific actions to address and transform some aspects of improvement by freely assuming one's own commitment proposals with the aim of modifying the presented reality, if deemed appropriate (last session).

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care Group
Description: They will be evaluated on baseline, final and follow up, and they will recieved basic nutritional and physical activity information.
Study: NCT06795893

Intervention type: DRUG
Intervention: Anifrolumab
Description: Anifrolumab is a human monoclonal antibody that binds to subunit 1 of the type 1 interferon receptor,which was developed based on the evidence supporting the role of type 1 interferon pathway in SLE. Clinical trial evidence from TULIP 1 and TULIP 2 have showed that monthly intravenous administration of anifrolumab led to a higher percentage of patients with a response, assessed with the British Isles Lupus Assessment Group-based Composite Lupus Assessment, compared with patients receiving placebo. Moreover, the phase II MUSE study showed that administration of anifrolumab resulted in substantially reduce disease activity, as measured by the SLE Responder Index,compared to patients receiving placebo. Anifrolumab was approved by the FDA and EMA in July 2021 and February 2022,respectively, for the treatment of adult patients with moderate to severe SLE who are receiving standard therapy.
Study: NCT06794645

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: pembrolizumab 200 mg by intravenous (IV) infusion on Day 1 of each 21-day treatment cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Phase 2
Description: pemetrexed 900 mg/m2 IV on Day 1 of each 21-day treatment cycle and supportive medications (folic acid, vitamin B12, and dexamethasone).
Study: NCT06797505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with new preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with new preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT05513365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg
Description: Dutasteride capsules (0.5 mg) once daily until progressive disease, intolerable toxicity, or investigator and/or patient decision to withdraw.
Study: NCT06282354

Intervention type: OTHER
Intervention: Type of post-operative appointment
Description: remote post-operative appointment for small or medium urooncology procedures
Study: NCT06797505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with present preparation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-rhGH with present preparation (T)
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Study: NCT06797128

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: One Anchor
Description: Participant will receive one standard anchor

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two Mini Anchors
Description: Participant will receive two mini anchors
Study: NCT06794528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RehbeCa mobile application
Description: The system consists of a mobile application (to be used by patients) and a web application (to be used by physiotherapists) that allows monitoring of the patient's performance without the need for attendance, thus facilitating telerehabilitation. The mobile application consists of a serious game that aims to induce the patient to perform neck exercises, adapting to their capacity and evolution at all times through artificial intelligence. The patient's interaction with the mobile application is based on the integration of a vision-based head-tracker to track the movements of the patient's head. The web application aims to provide professionals with a tool to monitor the evolution of their patients through the data captured by the mobile application.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Home exercise program
Description: Set of therapeutic exercises to be carried out at home. They are taught face-to-face, and also printed on a leaflet that is delivered to the participant.
Study: NCT06796387

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Implementation of SBAT
Description: For schools randomized to implementing SBAT, the program will include the components already available in comparison (usual care) schools (asthma symptom screening forms, access to telemedicine visits, and protocol for initiating DOT), as well as the following elements that will be facilitated with the support of an implementation team:~* Telemedicine asthma visits through school with primary care and/or specialist providers to prescribe needed initial medication as well as medication step-ups for DOT school-based DOT of preventive asthma medications~* Follow-up telemedicine asthma control assessments~* Centralized case management support~* Care coordination

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: During student health services orientation, the SBAT team will recommend school-based DOT for all children with persistent or poorly controlled asthma, and will provide a simple asthma screening survey to assess symptoms and a written protocol for initiating DOT. Telemedicine visits and DOT are available for all children in the school district, but the implementation team will not help to facilitate these components within the usual care schools.
Study: NCT06795230

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Muscle strengthening (BFRT)
Description: The experimental group will perform a low-intensity strengthening program (20% 1RM) in combination with the BFRT system consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, performing 4 sets of 30/15/15/15 repetitions as usual in this type of interventions.~Once the first exercise has been completed, a rest of 3 - 4 minutes should be taken depending on the fatigue perceived by the patient. Subsequently, the other two exercises will be performed following the scheme already outlined.~Taking into account the scientific evidence concerning the safety and adverse effects linked to the BFRT system, it is determined that the pressure applied in the experimental protocol will be 60% of the TRP of each subject, following the recommendations that locate the effective pressure between 50 - 80% of the TRP of each subject.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Description: The control group will perform a conventional muscle strengthening protocol consisting of the following exercises: palmar flexion and dorsal flexion; ulnar deviation and radial deviation; pronation and supination; elbow flexion and extension, with a dumbbell at 70% of 1RM, performing a total of 4 sets of 8 - 12 repetitions each, avoiding muscle failure in each set.
Study: NCT06797622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab deruxtecan (T-DXd)
Description: Trastuzumab deruxtecan (T-DXd)
Study: NCT06792825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Tafasitamab 12 mg/kg IV on Day 1, Day 8, Day 15 and day 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m2 IV on day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg PO Day 1 through Day 21

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 20 mg PO Day 1 through Day 21
Study: NCT06794333

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transperineal laser Ablation
Description: Treatments are performed with the combined EchoLaser EVO system (Elesta SpA - Calenzano, FI). The EchoLaser EVO consists of the Echolaser X4, a multi-source laser system with a wavelength of 1064 nm, and the Echolaser Smart Interface (ESI). The procedure are performed with the patient in the lithotomy position. Local anesthesia of the perineal region and periprostatic block with lidocaine is administered under ultrasound guidance. A catheter is placed during the irradiation to allow continuous irrigation of the urethra with saline solution, protecting the urethra from temperature rise. The Echolaser Smart Interface, defines: the number and positioning of fibers, the optimal dose, and the need for multiple pullbacks. 2 to 4 21G needles are inserted simultaneously (1 or 2 per lobe) in the peri-urethral area via transperineal ultrasound guidance. A 300-micron optical fiber will be placed in each needle. Each treatment delivers a maximum energy of 1800 J per fiber with a power of 3-5 W.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Rezum Vapor Therapy
Description: The treatment involves the insertion of a radiofrequency needle into the prostate tissue and the emission of water vapor. Treatment under local anesthesia/sedation. Treatment planning using the REZUM device, with the number of injections proportional to the recommended therapeutic scheme based on prostate volume (1 injection every centimeter starting 1 cm below the bladder neck and 1 cm in front of the verumontanum). Water vapor emission for 9-second intervals with a maximum of 9 applications per patient. Three-way bladder catheter to decrease local temperature. The bladder catheter will be removed 15 days after patient discharge. Regarding the REZUM, it is a system that uses sterile single-use handpieces available within the company, where a special optics is inserted for direct visualization. The handpiece features a device that allows the manual insertion of a needle into the prostate, from which water vapor is emitted for the described treatment.
Study: NCT06795854

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training
Description: Sessions will be conducted 3 times per week. Each 40-minute session will include a 5-minute warm-up involving fast walking, slow running, and stretching, followed by an active phase of continuous running. The running period will start at 15 minutes and increase by 2 minutes every two sessions until reaching 30 minutes. The session will conclude with a 5-minute cool-down of slow running and stretching. Exercise intensity will be maintained at 13-15 on the Borg Rate of Perceived Exertion, with continuous walking performed on a treadmill.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation techniques
Description: Relaxation techniques will include slow deep breathing and mindfulness meditation exercises. The breathing exercise will involve six cycles per minute, with a 4-second inhalation and a 6-second exhalation, repeated for 30 minutes, three sessions per week. Mindfulness meditation will include a stress and pain management program with sessions starting at 10-15 minutes and gradually increasing to 20-30 minutes, three times per week. Sessions will be conducted in a quiet, comfortable space, focusing on breath awareness, body scanning, thought observation, and optional loving-kindness meditation, concluding with a reflection period.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fodmap diet
Description: All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low fodmap diet
Description: All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low fodmap diet
Description: All groups will follow a low-FODMAP diet (LFD). The LFD will exclude foods that commonly aggravate IBS symptoms, such as those containing lactose (dairy), fructose (e.g., apples, pears), and sweeteners like sorbitol and xylitol. Female participants with a BMI of 25 to 29 will aim for a daily calorie intake of 1,800 to 2,200 calories, adjusted based on age, activity level, and metabolism, to maintain weight while managing IBS symptoms effectively.
Study: NCT06793033

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Advanced Cardiac Life Support (ACLS)
Description: Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Advanced Cardiac Life Support (ACLS)
Description: Standard of care Advanced Cardiac Life Support (ACLS) consists of cardiopulmonary resuscitation (CPR), airway management, ventilation and defibrillation.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aortic balloon occlusion (ABO)
Description: Aortic balloon occlusion (ABO) is a technique that diverts blood ﬂow towards the coronary and cerebral circulation. ABO is investigated as an adjunct to the treatment of cardiac arrest.~In this study ABO is performed using the NEURESCUE Catheter, which is inserted through an introducer in the femoral artery, and thereby inserted into the aorta during uninterrupted Advanced Cardiac Life Support (ACLS). The balloon is then temporarily inflated as an adjunct to the treatment of cardiac arrest.
Study: NCT06795087

Intervention type: OTHER
Intervention: Opioid Medication Disposal Education
Description: Education on opioid medication disposal will be provided in the form of a pamphlet created by Atrium Health based on FDA resources and will be given to all participants at discharge (cystectomy, nephrectomy, prostatectomy) beginning in the second year, approximately 13 months from when the first participant is enrolled or until a minimum of 100 evaluable participants are enrolled in the pre-education cohort, whichever occurs last.
Study: NCT06795633

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Holistic Care Program for High-Risk Pregnancies
Description: High-risk pregnant women admitted to the perinatology clinic participated in the Holistic Care Program for High-Risk Pregnancies in addition to the midwifery care provided in the clinic.
Study: NCT06788951

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: administration of oral carbohydrate solution to patients before coronary artery bypass graft surgery
Description: Oral carbohydrate solution will be administered to patients before coronary artery bypass graft operation and its effects on postoperative nausea-vomiting, hunger, thirst, physiological parameters and recovery will be evaluated.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: giving flavored water to patients before coronary artery bypass graft surgery
Description: The effects of flavored water given to patients before coronary artery bypass graft operation on postoperative nausea-vomiting, hunger and thirst,